Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 676 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 676 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total value of $30,338.88. Following the transaction, the chief financial officer now owns 61,959 shares of the company's stock, valued at approximately $2,780,719.92. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Akero Therapeutics Stock Down 2.9 %

NASDAQ AKRO traded down $1.29 during trading on Tuesday, reaching $43.53. 770,345 shares of the company's stock were exchanged, compared to its average volume of 812,716. The stock has a market cap of $3.47 billion, a P/E ratio of -11.61 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company has a 50 day moving average price of $42.44 and a two-hundred day moving average price of $34.02. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Remove Ads

Institutional Trading of Akero Therapeutics

Institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in Akero Therapeutics during the 4th quarter worth about $41,000. Sterling Capital Management LLC increased its position in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares in the last quarter. Quarry LP acquired a new stake in shares of Akero Therapeutics during the fourth quarter worth about $83,000. Summit Investment Advisors Inc. increased its position in shares of Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after purchasing an additional 450 shares in the last quarter. Finally, Summit Financial Wealth Advisors LLC acquired a new stake in shares of Akero Therapeutics during the third quarter worth about $205,000.

Analysts Set New Price Targets

AKRO has been the subject of several research analyst reports. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Canaccord Genuity Group lifted their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. UBS Group lifted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Citigroup lifted their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $76.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.